Suppr超能文献

经皮冠状动脉介入治疗与药物治疗稳定型冠状动脉疾病:未解之谜。

Percutaneous coronary intervention versus medical therapy in stable coronary artery disease: the unresolved conundrum.

机构信息

MedStar Cardiovascular Research Network, MedStar Heart Institute, MedStar Washington Hospital Center, Washington, DC.

出版信息

JACC Cardiovasc Interv. 2013 Oct;6(10):993-8. doi: 10.1016/j.jcin.2013.07.003.

Abstract

One of the major dilemmas facing physicians is what diagnostic and therapeutic approaches should be recommended to those stable coronary artery disease patients whose symptoms are adequately controlled on medical therapy. This study sought to assess the evidence-based data relating to whether: 1) all patients with significant coronary lesions (i.e., ischemia-producing) should undergo percutaneous coronary intervention (PCI); 2) the best therapeutic approach is optimal medical therapy; or 3) PCI should be performed, but only in certain subsets of patients. We reviewed all recent meta-analyses of prospective randomized trials that compared the outcomes of medical therapy and PCI in stable, symptomatically controlled, coronary artery disease patients. To provide greater insights to the clinician, we then analyzed, in depth, 3 comprehensive and widely quoted randomized trials. Review of recently published (2012) meta-analyses, and the detailed analyses of 3 widely quoted individual studies, indicate no difference exists between PCI and medical therapy in nonfatal MI or in all-cause or cardiovascular mortality. Thus, clinical equipoise exists: in other words, there is no evidence-based justification for adopting 1 therapeutic strategy over the other. Therefore, it is not inappropriate, until additional evidence emerges, for the responsible, experienced physician to weigh several sources of information in formulating a recommendation to the patient, even though definitive evidence-based data are not as yet available. Such sources may include assessment of the individual patient's clinical presentation, assessment of the severity of ischemia, and the patient's precise coronary anatomy. Critical for more-reliable decision making will be future development of accurate measures of the individual patient's risk of MI and/or death, whether by biomarker, imaging, or ischemia assessments.

摘要

医生面临的主要困境之一是,对于那些症状在药物治疗下得到充分控制的稳定型冠状动脉疾病患者,应该推荐哪些诊断和治疗方法。本研究旨在评估与以下问题相关的循证数据:1)所有有明显冠状动脉病变(即引起缺血)的患者是否都应接受经皮冠状动脉介入治疗(PCI);2)最佳治疗方法是最佳药物治疗;还是 3)应进行 PCI,但仅在某些特定患者亚组中进行。我们回顾了所有最近比较药物治疗和 PCI 在稳定型、症状控制良好的冠状动脉疾病患者中的疗效的前瞻性随机试验的荟萃分析。为了更深入地了解临床医生,我们然后深入分析了 3 项全面且广泛引用的随机试验。最近发表的(2012 年)荟萃分析的回顾,以及对 3 项广泛引用的单独研究的详细分析,表明 PCI 和药物治疗在非致死性心肌梗死或全因或心血管死亡率方面没有差异。因此,临床平衡存在:换句话说,没有循证依据支持采用一种治疗策略而不是另一种。因此,在出现额外证据之前,负责任的、有经验的医生权衡患者制定建议的多个信息来源是不合适的,即使目前还没有基于证据的明确数据。这些来源可能包括评估患者的临床情况、评估缺血的严重程度以及患者的确切冠状动脉解剖结构。对于更可靠的决策制定至关重要的是,未来将开发出更准确的个体患者心肌梗死和/或死亡风险的测量方法,无论是通过生物标志物、成像还是缺血评估。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验